crinetics pharmaceuticals
Why Crinetics (NASDAQ:CRNX) Nearly Doubled Today After Vertex’s US$10 Billion Takeover
Crinetics (NASDAQ:CRNX) nearly doubled on Tuesday, soaring about 98% to near US$83, after Vertex Pharmaceuticals agreed to buy the company in an all-cash deal. Vertex is paying US$85.00 per share, valuing Crinetics at roughly US$10 billion. For shareholders, this is a massive overnight win. But the more useful question for investors now is not why…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here